A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer

Simon P. Kim, Robert Jeffrey Karnes, Paul L. Nguyen, Jeanette Y. Ziegenfuss, R. Houston Thompson, Leona C. Han, Nilay D Shah, Marc C. Smaldone, Cary P. Gross, Igor Frank, Christopher J. Weight, Timothy J. Beebe, Jon C Tilburt

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: • To assess recommendations for prostate-specific antigen (PSA) screening in a national survey of radiation oncologists and urologists following the recent USA Preventive Services Task Force (USPSTF) grade D recommendation. Methods: • A random sample of 1366 radiation oncologists and urologists were identified from the American Medical Association Physician Masterfile. • From November 2011 to April 2012, a mail survey was sent to query PSA screening recommendations for men at average risk of prostate cancer for the following age groups: 40-49, 50-59, 60-69, 70-74, 75-79 and ≥80 years. • Multivariable logistic regression was used to test for differences in PSA-based screening recommendations by physician characteristics. Results: • Response rates were similar at 52% for radiation oncologists and urologists (P = 0.92). • Overall, 51.5% of respondents recommended PSA-based screening for men aged 40-49 years, while nearly all endorsed it for those aged 50-74 years (96.1% for 50-59, 97.3% for 60-69, and 87.7% for 70-74 years). • However, screening recommendations decreased to 43.9% and 12.8% for men aged 75-79 and ≥80 years, respectively. • On multivariable analysis, urologists were more likely to recommend screening for men aged 40-49 (odds ratio [OR] 3.09; P < 0.001) and 50-59 years (OR 3.81; P = 0.01), but less likely for men aged 75-79 (OR 0.66; P = 0.01) and ≥80 years (OR 0.45; P = 0.002) compared with radiation oncologists. Conclusion: • While radiation oncologists and urologists recommended PSA screening for men aged 50-69 years, there was less agreement about screening for younger (40-49 years old) and older (≥70 years) men at average risk for prostate cancer.

Original languageEnglish (US)
JournalBJU International
Volume113
Issue number5 B
DOIs
StatePublished - 2014

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Odds Ratio
Physicians
Postal Service
American Medical Association
Advisory Committees
Surveys and Questionnaires
Radiation Oncologists
Urologists
Age Groups
Logistic Models

Keywords

  • Outcomes
  • Prostate cancer
  • Prostate-specific antigen
  • Screening
  • Survey

ASJC Scopus subject areas

  • Urology

Cite this

A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. / Kim, Simon P.; Karnes, Robert Jeffrey; Nguyen, Paul L.; Ziegenfuss, Jeanette Y.; Thompson, R. Houston; Han, Leona C.; Shah, Nilay D; Smaldone, Marc C.; Gross, Cary P.; Frank, Igor; Weight, Christopher J.; Beebe, Timothy J.; Tilburt, Jon C.

In: BJU International, Vol. 113, No. 5 B, 2014.

Research output: Contribution to journalArticle

Kim, SP, Karnes, RJ, Nguyen, PL, Ziegenfuss, JY, Thompson, RH, Han, LC, Shah, ND, Smaldone, MC, Gross, CP, Frank, I, Weight, CJ, Beebe, TJ & Tilburt, JC 2014, 'A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer', BJU International, vol. 113, no. 5 B. https://doi.org/10.1111/bju.12422
Kim, Simon P. ; Karnes, Robert Jeffrey ; Nguyen, Paul L. ; Ziegenfuss, Jeanette Y. ; Thompson, R. Houston ; Han, Leona C. ; Shah, Nilay D ; Smaldone, Marc C. ; Gross, Cary P. ; Frank, Igor ; Weight, Christopher J. ; Beebe, Timothy J. ; Tilburt, Jon C. / A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. In: BJU International. 2014 ; Vol. 113, No. 5 B.
@article{f3c60d1484dd4eda99854cc0f96db316,
title = "A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer",
abstract = "Objective: • To assess recommendations for prostate-specific antigen (PSA) screening in a national survey of radiation oncologists and urologists following the recent USA Preventive Services Task Force (USPSTF) grade D recommendation. Methods: • A random sample of 1366 radiation oncologists and urologists were identified from the American Medical Association Physician Masterfile. • From November 2011 to April 2012, a mail survey was sent to query PSA screening recommendations for men at average risk of prostate cancer for the following age groups: 40-49, 50-59, 60-69, 70-74, 75-79 and ≥80 years. • Multivariable logistic regression was used to test for differences in PSA-based screening recommendations by physician characteristics. Results: • Response rates were similar at 52{\%} for radiation oncologists and urologists (P = 0.92). • Overall, 51.5{\%} of respondents recommended PSA-based screening for men aged 40-49 years, while nearly all endorsed it for those aged 50-74 years (96.1{\%} for 50-59, 97.3{\%} for 60-69, and 87.7{\%} for 70-74 years). • However, screening recommendations decreased to 43.9{\%} and 12.8{\%} for men aged 75-79 and ≥80 years, respectively. • On multivariable analysis, urologists were more likely to recommend screening for men aged 40-49 (odds ratio [OR] 3.09; P < 0.001) and 50-59 years (OR 3.81; P = 0.01), but less likely for men aged 75-79 (OR 0.66; P = 0.01) and ≥80 years (OR 0.45; P = 0.002) compared with radiation oncologists. Conclusion: • While radiation oncologists and urologists recommended PSA screening for men aged 50-69 years, there was less agreement about screening for younger (40-49 years old) and older (≥70 years) men at average risk for prostate cancer.",
keywords = "Outcomes, Prostate cancer, Prostate-specific antigen, Screening, Survey",
author = "Kim, {Simon P.} and Karnes, {Robert Jeffrey} and Nguyen, {Paul L.} and Ziegenfuss, {Jeanette Y.} and Thompson, {R. Houston} and Han, {Leona C.} and Shah, {Nilay D} and Smaldone, {Marc C.} and Gross, {Cary P.} and Igor Frank and Weight, {Christopher J.} and Beebe, {Timothy J.} and Tilburt, {Jon C}",
year = "2014",
doi = "10.1111/bju.12422",
language = "English (US)",
volume = "113",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "5 B",

}

TY - JOUR

T1 - A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer

AU - Kim, Simon P.

AU - Karnes, Robert Jeffrey

AU - Nguyen, Paul L.

AU - Ziegenfuss, Jeanette Y.

AU - Thompson, R. Houston

AU - Han, Leona C.

AU - Shah, Nilay D

AU - Smaldone, Marc C.

AU - Gross, Cary P.

AU - Frank, Igor

AU - Weight, Christopher J.

AU - Beebe, Timothy J.

AU - Tilburt, Jon C

PY - 2014

Y1 - 2014

N2 - Objective: • To assess recommendations for prostate-specific antigen (PSA) screening in a national survey of radiation oncologists and urologists following the recent USA Preventive Services Task Force (USPSTF) grade D recommendation. Methods: • A random sample of 1366 radiation oncologists and urologists were identified from the American Medical Association Physician Masterfile. • From November 2011 to April 2012, a mail survey was sent to query PSA screening recommendations for men at average risk of prostate cancer for the following age groups: 40-49, 50-59, 60-69, 70-74, 75-79 and ≥80 years. • Multivariable logistic regression was used to test for differences in PSA-based screening recommendations by physician characteristics. Results: • Response rates were similar at 52% for radiation oncologists and urologists (P = 0.92). • Overall, 51.5% of respondents recommended PSA-based screening for men aged 40-49 years, while nearly all endorsed it for those aged 50-74 years (96.1% for 50-59, 97.3% for 60-69, and 87.7% for 70-74 years). • However, screening recommendations decreased to 43.9% and 12.8% for men aged 75-79 and ≥80 years, respectively. • On multivariable analysis, urologists were more likely to recommend screening for men aged 40-49 (odds ratio [OR] 3.09; P < 0.001) and 50-59 years (OR 3.81; P = 0.01), but less likely for men aged 75-79 (OR 0.66; P = 0.01) and ≥80 years (OR 0.45; P = 0.002) compared with radiation oncologists. Conclusion: • While radiation oncologists and urologists recommended PSA screening for men aged 50-69 years, there was less agreement about screening for younger (40-49 years old) and older (≥70 years) men at average risk for prostate cancer.

AB - Objective: • To assess recommendations for prostate-specific antigen (PSA) screening in a national survey of radiation oncologists and urologists following the recent USA Preventive Services Task Force (USPSTF) grade D recommendation. Methods: • A random sample of 1366 radiation oncologists and urologists were identified from the American Medical Association Physician Masterfile. • From November 2011 to April 2012, a mail survey was sent to query PSA screening recommendations for men at average risk of prostate cancer for the following age groups: 40-49, 50-59, 60-69, 70-74, 75-79 and ≥80 years. • Multivariable logistic regression was used to test for differences in PSA-based screening recommendations by physician characteristics. Results: • Response rates were similar at 52% for radiation oncologists and urologists (P = 0.92). • Overall, 51.5% of respondents recommended PSA-based screening for men aged 40-49 years, while nearly all endorsed it for those aged 50-74 years (96.1% for 50-59, 97.3% for 60-69, and 87.7% for 70-74 years). • However, screening recommendations decreased to 43.9% and 12.8% for men aged 75-79 and ≥80 years, respectively. • On multivariable analysis, urologists were more likely to recommend screening for men aged 40-49 (odds ratio [OR] 3.09; P < 0.001) and 50-59 years (OR 3.81; P = 0.01), but less likely for men aged 75-79 (OR 0.66; P = 0.01) and ≥80 years (OR 0.45; P = 0.002) compared with radiation oncologists. Conclusion: • While radiation oncologists and urologists recommended PSA screening for men aged 50-69 years, there was less agreement about screening for younger (40-49 years old) and older (≥70 years) men at average risk for prostate cancer.

KW - Outcomes

KW - Prostate cancer

KW - Prostate-specific antigen

KW - Screening

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=84902332551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902332551&partnerID=8YFLogxK

U2 - 10.1111/bju.12422

DO - 10.1111/bju.12422

M3 - Article

VL - 113

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 5 B

ER -